Expanded Coverage on NRDL for ELUNATE & ORPATHYS

Summary by AI BETAClose X

HUTCHMED announced ELUNATE, ORPATHYS and SULANDA will remain on China’s National Reimbursement Drug List effective 1 January 2027, with ELUNATE newly reimbursed for advanced/metastatic renal cell carcinoma in combination with sintilimab and ORPATHYS newly reimbursed for EGFR‑mutant NSCLC with MET amplification (and renewed for MET exon 14 skipping); these updates preserve coverage under current multi‑year agreements and could expand patient access within China’s basic medical insurance covering 1.33 billion people (~95% of the population).

Disclaimer*

UK 100

Latest directors dealings